Hepatitis A vaccination targeting adults (or adult risk-groups like e.g. travellers, health care workers, soldiers or teachers) could be considered an alternative to a universal infant or adolescent vaccination program in low endemic countries. We estimated the current disease burden of hepatitis A in Belgium, and evaluated whether adult vaccination is cost-effective. We used a Markov cohort model to simulate the costs and effects of (1) vaccination of adults and (2) serological screening of adults and vaccination of susceptibles and compared these with the current situation. The results indicated that these expanded vaccination strategies are not cost-effective in the epidemiological circumstances of a typical low-endemic western country. In order to gain 1 quality-adjusted life year the health care payer would have to pay 185,000€ for vaccination and 223,000€ for screening and vaccination of seronegatives. For adult vaccination to be cost-effective, risk-groups would need to be exposed to a force of infection that is 3.5-4 times higher than currently estimated in the general population; or the total costs of vaccination would have to drop with approximately 75%.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2012.07.049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and incidence of HPV-related dysplasia of oropharyngeal, cervical, and anal mucosae in Spanish people living with HIV (PLHIV).
AIDS
January 2025
Internal Medicine Department, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitario de Granada (IBS-Granada), Spain.
Background: Objectives were to determine the prevalence/incidence of HPV-related dysplasia and clearance/acquisition rates of high-risk HPV (HR-HPV) genotypes in genital mucosa of women-LHIV and oropharyngeal and anal mucosa of PLHIV and to evaluate factors related to HR-HPV infection in oropharyngeal mucosa at 12-months.
Material And Methods: Prospective, longitudinal study with 12-month follow-up, enrolled PLHIV between December 2022 and April 2023. At baseline and 12-months, HIV-related clinical and analytical variables were recorded, oropharyngeal mucosa exudates were taken for polymerase chain reaction (PCR) studies for HPV and other sexually transmitted infections, while anal and female genital samples were self-sampled for HPV detection and genotyping by PCR and thin-layer cytology.
The increasing threat of vaccine-preventable diseases in Lebanon.
East Mediterr Health J
December 2024
Department of Public Health, Qatar University.
Putting governance into practice: The engagement of private health sector for Universal Health Coverage and health security.
East Mediterr Health J
December 2024
Assistant Director-General of the Universal Health Coverage, Life Course Division, World Health Organization Headquarters, Geneva.
The 'next pandemic' has become a common terminology increasingly used in media and academic literature. Emerging pathogens pose a considerable risk to our increasingly globalised communities and there is a need for adequate preparedness for them. However, in Lebanon, like in many countries, the 'next' pathogens, such as the measles pathogen, posing a dire threat to public health are neither emerging nor re-emerging; they are common, endemic and vaccine-preventable.
View Article and Find Full Text PDFAssessing healthcare workers' knowledge and confidence in the diagnosis, management and prevention of Monkeypox.
World J Clin Cases
January 2025
Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital of Southern Medical University, Shenzhen 518101, Guangdong Province, China.
Background: Monkeypox (Mpox), is a disease of global public health concern, as it does not affect only countries in western and central Africa.
Aim: To assess Burundi healthcare workers (HCWs)s' level of knowledge and confidence in the diagnosis and management of Mpox.
Methods: We conducted a cross-sectional study an online survey designed mainly from the World Health Organization course distributed among Burundi HCWs from June-July 2023.
A human monoclonal antibody isolated from Japanese encephalitis virus vaccine-vaccinated volunteer neutralizing various flaviviruses.
Front Microbiol
December 2024
School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
Introduction: Japanese encephalitis virus (JEV) and Zika virus (ZIKV) are prevalent in over 80 countries or territories worldwide, causing hundreds of thousands of cases annually. But currently there is a lack of specific antiviral agents and effective vaccines.
Methods: In the present study, to identify human neutralizing monoclonal antibody (mAb) against JEV or/and ZIKV, we isolated ZIKV-E protein-binding B cells from the peripheral venous blood of a healthy volunteer who had received the JEV live-attenuated vaccine and performed 10× Genomics transcriptome sequencing and BCR sequencing analysis, we then obtained the V region amino acid sequences of a novel mAb LZY3412.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!